Désolé, cet article est seulement disponible en EN.
Cliquez pour voir le graph
Connexions
Présentation
Membres

Michael White
Responsable de Structure
Responsable
Projets
Projet Transversal
Publications
Télécharger-
2025
-
2024Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study., Lancet Child Adolesc Health 2024 Oct; 8(10): 721-729.
-
2024Title evaluation of FluSight influenza forecasting in the 2021-22 and 2022-23 seasons with a new target laboratory-confirmed influenza hospitalizations., Nat Commun 2024 Jul; 15(1): 6289.
-
2024Challenges of COVID-19 Case Forecasting in the US, 2020-2021., PLoS Comput Biol 2024 May; 20(5): e1011200.
-
2024Measuring effects of ivermectin-treated cattle on potential malaria vectors in Vietnam: A cluster-randomized trial., PLoS Negl Trop Dis 2024 Apr; 18(4): e0012014.
-
2024Caveolin-1 protects endothelial cells from extensive expansion of transcellular tunnel by stiffening the plasma membrane., Elife 2024 Mar; 12(): .
-
2024Antibody-Dependent Respiratory Burst against Plasmodium falciparum Merozoites in Individuals Living in an Area with Declining Malaria Transmission., Vaccines (Basel) 2024 Feb; 12(2): .
-
2024Evaluating vector competence for Yellow fever in the Caribbean., Nat Commun 2024 Feb; 15(1): 1236.
-
2024Disease-specific plasma protein profiles in patients with fever after traveling to tropical areas., Eur J Immunol 2024 Feb; (): e2350784.
-
2024PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial., NPJ Vaccines 2024 Jan; 9(1): 10.
-
+Voir la liste complète de publications